linjc16/ctgov huggingface dataset:
How to Provide Vascular Control of Splenic Artery Aneurysm? Report of Two Cases

Study Overview
=================
Brief Summary
-----------------
Spleen artery aneurysm represents the most common visceral aneurysm and the third most common splanchnic aneurysm. Most patients have no symptoms and are diagnosed as a part of other diagnostic focuses and examinations. The investigators present two patients with splenic artery aneurysms localized in the splenic hilum, who auspiciously undergo laparoscopic splenectomies with hem-o-lock clips in the vascular hilum without complications. These two cases showed that in addition to the numerous advantages of minimally invasive approaches, there is the possibility to improve laparoscopic technique in terms of safety and economic reasons by using hem - o - lock clips as a hemostatic technique securing the vascular elements of the splenic hilum.

Official Title
-----------------
How to Provide Vascular Control of Splenic Artery Aneurysm? Report of Two Cases

Conditions
-----------------
Arterial Splenic Aneurysm

Intervention / Treatment
-----------------
* Procedure: Laparoscopic Splenectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults patients (>18 year old) with splenic arterial aneurysms Exclusion Criteria: Patients younger than 18 years old. Patients without splenic arterial aneurysms
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Laparoscopic Splenectomy|Laparoscopic splenectomy by ligating the splenic artery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arterial Splenic Aneurysm | Asses the splenic hilium after operating a splenic arterial aneurysm. It will be measure by the follow up of the patient, by consult and physical examination. | July 2020 |
Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Overview
=================
Brief Summary
-----------------
To demonstrate the efficacy of ROX AC1 (with respect to exercise capacity and quality of life) in patients with COPD.

Detailed Description
-----------------
Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease that leads to irreversible changes in the lung structure, but also to systemic changes in the body that can influence the severity of the disease. The irreversible changes to the lungs can be seen in limitations in the pulmonary function. The purpose of this clinical investigation is to evaluate the performance and efficacy of the ROX AC1 on exercise capacity and respiratory quality of life.

Official Title
-----------------
A Study of the Effect of the ROX Percutaneous Arteriovenous Fistula System (ROX AC1) on Exercise Capacity and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Device: Arteriovenous Fistula (ROX AC1)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of advanced Chronic Obstructive Pulmonary Disease (COPD) must be made on the basis of current findings, medical history and physical examination. Exclusion Criteria: Subject not qualifying because of physical or psychological condition that may put them at risk of participating.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental: Group A Anastomotic Coupler<br>Device: ROX Anastomotic Coupler System (ACS). The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein). | Device: Arteriovenous Fistula (ROX AC1)<br>* The percutaneous creation of an arteriovenous fistula.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in exercise capacity. |  | 12 weeks post-procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in quality of life. |  | 12 weeks post-procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung Disease, Chronic Airflow Obstruction, Chronic Bronchitis, Chronic Emphysema
Medical Follow-up and Self-medication Among Medical Students

Study Overview
=================
Brief Summary
-----------------
As health actors, medical students educate patients to have regular medical follow-up and give them justified medical prescriptions. Regarding their own health, medical students do not seem to apply these same principles. The medical follow-up of medical students seems insufficient, which can be explained by the lack of medical follow-up by occupational medicine, a consequent work time, but also the fear of judgment by colleagues Moreover, medical student have an easy access to all types of prescriptions and therefore the ease of self-prescription and self-medication. Medical students may also overestimate their medical knowledge and may not be objective about their symptomatology.

Detailed Description
-----------------
The aim of the study will be to describe medical follow-up and self-medication among medical students

Official Title
-----------------
Medical Follow-up and Self-medication Among Medical Students

Conditions
-----------------
Medical Student

Intervention / Treatment
-----------------
* Other: medical students group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: medical student in general practice or in specialty medicine agreeing to participate in the study Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: medical students group|medical student in general practice or in specialty medicine|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| self-medication | Number of medical students with prescription for themself of a medical treatment | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| self-prescription | Number of medical students with prescription for themself of an biological analysis and/or a medical imaging | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
medical student, medical follow-up, self medication
To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets

Study Overview
=================
Brief Summary
-----------------
To demonstrate the relative bioavailability of Cyclobenzaprine HCl tablets.

Official Title
-----------------
Bioavailability of Cyclobenzaprine HCl Tablets

Conditions
-----------------
Depression

Intervention / Treatment
-----------------
* Drug: Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories
* Drug: Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: Positive test results for HIV or hepatitis B or C. Treatment for drug or alcohol dependence.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories | Drug: Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories<br> <br> |
| Active Comparator: 2<br>Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme | Drug: Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence based on AUC and Cmax |  | 33 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Antidepressant
Tahini and Dermatitis in Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This study aimed to investigate the effect of tahini on acute radiation dermatitis in breast cancer (BC) patients undergoing radiotherapy (RT). 50 eligible BC patients will randomly assign to consume tahini 48 gr per day during and 1 week after RT or with no intervention (control group). The radiation dermatitis will be assessed weekly according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales.

Official Title
-----------------
The Effects of Tahini Consumption on Radiotherapy Induced Dermatitis in Breast Cancer - A Pilot Study

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Dietary Supplement: tahini
* Other: control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women with Brest Cancer undergoing adjutant Radiation therapy Exclusion Criteria: previous history of RT, MRM, concomitant presence of two or more malignant tumors metastasis to other areas allergy or intolerance to tahini skin diseases and wounds severe liver and renal disease autoimmune diseases pregnant and lactating women those who treated with hypo fraction RT

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: tahini<br>48 gr per day | Dietary Supplement: tahini<br>* 48 grams tahini<br>|
| Placebo Comparator: control<br>no intervention | Other: control<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| severity of dermatitis | Change from Baseline severity at 4 weeks. The radiation dermatitis will be assessed according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales | 4 weeks |
A Cohort Study of Hydatidiform Mole

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to construct a cohort for the hydatidiform mole.

Detailed Description
-----------------
After being informed about the study and potential risks, all patients who meet the eligibility requirements will be enrolled.

Official Title
-----------------
A Multi-center Cohort Study of Hydatidiform Mole

Conditions
-----------------
Hydatidiform Mole

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are diagnosed with hydatidiform mole (including: complete hydatidiform mole/partial hydatidiform mole; one of twins with hydatidiform mole; ectopic pregnancy hydatidiform mole; macroscopic or microscopic hydatidiform changes indicating early complete or partial hydatidiform mole can not be excluded; atypical placental site nodule) for the first time; Age 13-55 years old; Obtain informed consent and sign an informed consent form Exclusion Criteria: Patients who are unable to cooperate with the investigation such as mental disorders or cognitive impairment No histopathology diagnosis; Patients with other malignancies

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|This is a prospective observational study with no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Malignant trophoblastic tumor | Patients with hydatidiform mole develop malignant trophoblastic tumor. The Federation of International of Gynecologists and Obstetricians criteria for diagnosis of postmolar gestational trophoblastic neoplasia were as follows: (1) when the plateau of human chorionic gonadotrophin (hCG) lasts for four measurements over a period of 3 weeks or longer; that is, days 1, 7, 14, 21; (2) when there is a rise in hCG for three consecutive weekly measurements over at least a period of 2 weeks or more; days 1, 7, 14; (3) If there is a histologic diagnosis of choriocarcinoma. | 4.5 years |
A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) properties of FIAsp (faster-acting insulin aspart) in children, adolescents and adults with type 1 diabetes.

Official Title
-----------------
A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 1

Intervention / Treatment
-----------------
* Drug: Faster-acting insulin aspart
* Drug: insulin aspart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female aged 6-64 years (both inclusive) at the time of signing informed consent Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months Body mass index (BMI) for children and adolescents (male and female) between the 3rd and 97th BMI percentile and for adults equal to or below 28.0 kg/m^2 Exclusion Criteria: Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe daily) Not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: FIAsp<br>Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days | Drug: Faster-acting insulin aspart<br>* A single dose will be administered subcutaneously (s.c. under the skin)<br>|
| Active Comparator: NovoRapid®<br>Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days | Drug: insulin aspart<br>* A single dose will be administered subcutaneously (s.c. under the skin)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the serum insulin aspart concentration-time curve |  | From 0 to 12 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum observed serum insulin aspart concentration |  | From 0-12 hours |
Pediatric Intubation Among Nursing

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to compare time, success rates of video laryngoscope and direct laryngoscope for the emergency intubation with an immobilized cervical spine in a standardized pediatric manikin model.

Official Title
-----------------
Coparison of Miller and CoPilot Laryngoscopes for Intubation by Nurses During Child Chest Compression. A Manikin Study

Conditions
-----------------
Cardiac Arrest, Intubation, Endotracheal

Intervention / Treatment
-----------------
* Device: MIL
* Device: CoPilot


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: give voluntary consent to participate in the study minimum 1 year of work experience in nursing Exclusion Criteria: not meet the above criteria wrist or low back diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Child ETI with chest compressions<br>endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.). | Device: MIL<br>* direct laryngoscopy<br>* Other names: Miller laryngoscope;Device: CoPilot<br>* video laryngoscopy<br>* Other names: CoPilot VideoLaryngoscope;|
| Experimental: Child ETI without chest compressions<br>Endotracheal intubation of child mannikin during resuscitation without chest compressions. | Device: MIL<br>* direct laryngoscopy<br>* Other names: Miller laryngoscope;Device: CoPilot<br>* video laryngoscopy<br>* Other names: CoPilot VideoLaryngoscope;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success of intubation | effectiveness of the first, second and third intubation attempts and overall effectiveness of intubation by participants using four intubation devices. | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to intubation | time from insertion of the blade to the first manual ventilation of the manikin´s lungs. If time of intubation is over than 60 seconds, attempt was recognized as failure.If the examinee failed at all attempts, the case was excluded from the time calculations. | 1 day |
Voiding Disorders in Children After Sacrococcygeal Teratoma Resection

Study Overview
=================
Brief Summary
-----------------
Sacrococcygeal teratomas are the most common neonatal tumors and require rapid and complete resection. Tumor nerve compression and pelvic surgical sequelae may lead to many and varied voiding disorders. Data concerning long-term vesico-sphincteric disorders are conflicting. Some studies find good functional results [Cozzi et al., 2008; Draper et al., 2009]. However other authors reveal neurologic bladder with detrusor sphincter dyssynergia [Hambraeus et al., 2018] and rise concerned about long-term renal function [Khanna et al., 2019; Rehfuss et al., 2020] even in the absence of clinical voiding disorders. Most of studies include young patients with other malformations such as anorectal malformations or dysraphisms which may impact the results. The main objective is to assess bladder dysfunction in children aged 6 to 18 years after isolated sacrococcygeal teratoma resection.

Official Title
-----------------
Voiding Disorders in Children After Sacrococcygeal Teratoma Resection

Conditions
-----------------
Sacrococcygeal Teratoma, Neurogenic Bladder, Voiding Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Children aged 6 to 18 history of sacrococcygeal teratoma resection Exclusion criteria: Associated anorectal malformation Associated neurological pathology

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of voiding disorders | Presence of voiding disorders will be assessed by the scale: Dysfonctional voiding scoring system | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of defecation disorders | The Presence of defecation disorders will be assessed by the scale: Bristol stool scale | Day 1 | 
| Presence of secondary neurological bladder | the Presence of secondary neurological bladder will be assessed by the uroflowmetry | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Teratoma, sacrococcygeal region, urinary incontinence, neurogenic bladder, children